A Phase 2, 24-Week, Adaptive, Open Label, Sequential Cohort Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06730512 Following Multiple Doses in Adult Subjects With Focal Segmental Glomerulosclerosis (FSGS)

A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)

A Phase 2, 24-Week, Adaptive, Open Label, Sequential Cohort Trial to Evaluate the Efficacy, Safety, Tolerability and
Pharmacokinetics of PF-06730512 Following Multiple Doses in Adult Subjects With Focal Segmental Glomerulosclerosis (FSGS)

Category & Conditions: Infections and Infectious Diseases

Medicine: PF-06730512

ClinicalTrials.gov Identifier (NCT): NCT03448692

Protocol ID: C0221002

Print Download

Open Plain Language Summary Result: Click here